Skip to content
New generation mozzarella cultures offer savings and optimum consistency

Press release -

New generation mozzarella cultures offer savings and optimum consistency

Chr. Hansen's new freeze-dried culture blends are optimized for cost-efficient production of mozzarella.

“Our new culture blends are targeted specifically at giving the best possible robustness against bacteriophages, so the pasta filata dairies converting from bulk starter to the new FD-DVS STI cultures can eliminate the risk of having dead vats or downgrading of cheeses,” points out Nanna Borne, Marketing Manager, Cheese Cultures, Chr. Hansen. “Naturally, we expect this to find favor with the Southern European producers of mozzarella but also South American dairies have been requesting cultures of this sort,” Nanna Borne explains.

Cost attractive features

The core properties of the ‘STI’ culture blends make them attractive in times with intensified focus on cost:

  • Exceptional phage robustness due to the presence of multiple strains in each blend. The synergy between strains mean excellent performance and no delays or scrap in production due to poor acidification;
  • The anti-bacteriophage properties of the new blends make them very suitable at dairies where the cheese production process is automated in a dry matting conveyor;
  • The availability of three different blends makes it possible for the cheese manufacturer to rotate and thereby minimize the risk of propagation of bacteriophages in the production environment;
  • The cultures are available in various pack sizes fitted to the average vat sizes of small and mid-sized dairies. This makes them convenient to use compared to bulk starter;
  • The Direct Vat Set® production technology offers a number of advantages in terms of flexibility of use, consistent performance, possibility of using customized culture blends, and no investment in bulk starter equipment.



Format benefits

“The compact freeze-dried format makes it easy for the cheese manufacturer to store and handle the STI starter cultures,” Nanna Borne adds. “Comparing parallel productions of cheese made with the STI blends and traditional bulk starter, the STI cultures proved faster in acidifying the cheese milk. Compared to handling bulk starter only one pouch of STI culture (< 100 grams) is needed to inoculate a tank of 5,000 liters of milk, where traditionally 5 liters of bulk starter was needed to obtain the same effect.”

Meeting customer expectations

Including mozzarella, pizza cheese and provolone the pasta filata segment makes up 12% of total European cheese production; 900.000 tons are produced annually. The main part of the traditional fresh mozzarella is produced at approx. 50 dairies primarily in Italy.

Abbasciano Dairy in Trento, Northern Italy is one of three Italian dairies that have trialed the new culture blends.

Piero Denti, Dairy Manager at Abbasciano Dairy says: “Having tested the ‘STI’ blends I can say that they match the high quality level that we are used to from Chr. Hansen cultures. We registered no phage activity and the end-product — fresh table mozzarella — had excellent structure and delicious aroma.”

Mission completed

“For the development of these blends, a great effort was given to exploit the Chr. Hansen palette of thermophilic freeze-dried strains in an intelligent and effective way. The goals for maximum diversity and optimized phage robustness are achieved in these three new blends. At the same time, the blends are designed to perform equally and similarly to existing Chr. Hansen cultures. No adjustments are needed in terms of dosaging compared to existing blends.” says Jeorgos Trihaas, Development Scientist, Chr. Hansen.


The new culture blends are named FD-DVS STI-12, FD-DVS STI-13 and FD-DVS STI-14. The blends are based on the same principles as the former Chr. Hansen pasta filata culture generation with a very positive track record in the mozzarella market during the last decade.

Topics


Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.

Contacts

Helle Rexen

Helle Rexen

Press contact Media relations officer +45 20 74 28 40

About us

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Chr. Hansen Holding A/S

Boege Allé 10-12
DK-2970 Hoersholm
Denmark